NDA 203697 · Plx Pharma
Vazalore
Aspirin · Oral
Last checked: Nov 20, 2026Latest source record: Oct 3, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2013
Jan 14, 2013
Approved uses
1
Original approval plus efficacy supplements
Registered trials
1,694
423 Phase 3, 202 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 14, 2013 Original approval · Type 3 - New Dosage Form LabelSummary ReviewLetter
2 products under this application
- VAZALORE · ASPIRIN 81MG · CAPSULE, ORAL · Over-the-counter
- VAZALORE · ASPIRIN 325MG · CAPSULE, ORAL · Over-the-counter
Clinical trials
Interventional ClinicalTrials.gov studies with "Aspirin" as an intervention, any sponsor and status, largest first.
- Randomised Evaluation of COVID-19 TherapyPivotal-lookingRecruiting
University of OxfordAcademic, hospital or other
NCT04381936 · 70,000 participants (planned) · Start Mar 19, 2020 · Primary completion Sep 30, 2028
Drug: Lopinavir-Ritonavir; Corticosteroid and 20 more · For: Pneumonia
Sites: Brussels, Belgium; Tallinn, Estonia; Paris, France · 16 sites in all
- Efficacy and Safety of Adding Clopidogrel to Aspirin or Use of Metoprolol in Myocardial InfarctionPivotal-lookingCompleted
University of OxfordAcademic, hospital or other
NCT00222573 · 46,000 participants · Start Jul 1999
Drug: clopidogrel and metoprolol · For: Acute Myocardial Infarction
Sites: Beijing, China; Oxford, United Kingdom
- Women's Health Study (WHS): A Randomized Trial of Low-dose Aspirin and Vitamin E in the Primary Prevention of Cardiovascular Disease and CancerPivotal-lookingCompleted
Brigham and Women's HospitalAcademic, hospital or other
NCT00000479 · 39,876 participants · Start Sep 1992 · Primary completion Mar 2004
Drug: Aspirin; Vitamin E · For: Cardiovascular Diseases; Cerebrovascular Disorders; Coronary Disease and 4 more
- Randomized Comparison of Morning Versus Bedtime Administration of Aspirin: A Cardiovascular Circadian Chronotherapy (C3) TrialPivotal-lookingRecruiting
Tor Biering-SørensenAcademic, hospital or other
NCT05932472 · 32,706 participants (planned) · Start Jan 15, 2024 · Primary completion Jan 15, 2027
Drug: Aspirin · For: Atherosclerosis; Cardiovascular Diseases; Drug Effect
Sites: Hellerup, Denmark
- Helicobacter Eradication Aspirin TrialPivotal-lookingCompleted
University of NottinghamAcademic, hospital or other
NCT01506986 · 30,024 participants · Start Mar 2012 · Primary completion Oct 31, 2017
Drug: Lansoprazole 30mg, Clarithromycin 500mg, Metronidazole 400mg; Placebo lansoprazole 30mg, clarithromycin 500mg, metronidazole 400mg · For: Gastrointestinal Ulcer Haemorrhage; Bacterial Infection Due to Helicobacter Pylori (H. Pylori)
Sites: Belfast, United Kingdom; Birmingham, United Kingdom; Durham, United Kingdom · 6 sites in all
- Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery DiseasePivotal-lookingCompleted
BayerBayer (BAYRY)
NCT01776424 · 27,395 participants · Start Feb 28, 2013 · Primary completion Jul 21, 2017
Drug: Rivaroxaban (Xarelto, BAY59-7939); Rivaroxaban (Xarelto, BAY59-7939) and 5 more · For: Prevention & Control
Sites: Birmingham, Alabama; Mobile, Alabama; Anaheim, California · 565 sites in all
- The Dual Antiplatelet Therapy Study (DAPT Study)Pivotal-lookingCompleted
Baim Institute for Clinical ResearchAcademic, hospital or other
NCT00977938 · 25,682 participants · Start Oct 2009 · Primary completion Jun 2014
Drug: Placebo & Aspirin; Clopidogrel & Aspirin, Prasugrel & Aspirin · For: Coronary Artery Disease
Sites: Fairhope, Alabama; Gilbert, Arizona; Phoenix, Arizona · 256 sites in all
- Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of AspirinPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT01225562 · 21,379 participants · Start Oct 2010 · Primary completion Dec 2014
Drug: Ticagrelor 90 mg; Ticagrelor 60 mg and 1 more · For: Myocardial Infarction; Cardiovascular Death; Atherothrombosis and 1 more
Sites: Alexander City, Alabama; Athens, Alabama; Birmingham, Alabama · 826 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Aspirin for Primary Atherosclerotic Cardiovascular Disease Prevention as Baseline Risk Increases: A Meta-Regression Analysis.
Nudy M, Cooper J, Ghahramani M, et al. · Am J Med 2020 · Meta-Analysis, Systematic Review
- Clopidogrel versus aspirin for secondary prevention of coronary artery disease: a systematic review and individual patient data meta-analysis.
Valgimigli M, Choi KH, Giacoppo D, et al. · Lancet 2025 · Systematic Review, Meta-Analysis
- Primary Prevention of Cardiovascular Events with Aspirin: Toward More Harm than Benefit-A Systematic Review and Meta-Analysis.
Christiansen M, Grove EL, Hvas AM · Semin Thromb Hemost 2019 · Meta-Analysis, Systematic Review
- Ticagrelor and Aspirin or Aspirin Alone after Coronary Surgery for Acute Coronary Syndrome.
Jeppsson A, James S, Moller CH, et al. · N Engl J Med 2025 · Clinical Trial, Phase II, Comparative Study
- Aspirin plus clopidogrel versus aspirin mono-therapy for ischemic stroke: a meta-analysis.
Ye MB, Chen YL, Wang Q, et al. · Scand Cardiovasc J 2019 · Meta-Analysis, Systematic Review
- Clinical Effectiveness and Safety of Aspirin for Venous Thromboembolism Prophylaxis After Total Hip and Knee Replacement: A Systematic Review and Meta-analysis of Randomized Clinical Trials.
Matharu GS, Kunutsor SK, Judge A, et al. · JAMA Intern Med 2020 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Plx Pharma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.